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Objective:  To determine the incidence of prostate cancer identified on holmium 
enucleation of the prostate (HoLEP) specimens and evaluate variables associated with 
prostate cancer identification. 
Methods:  All patients undergoing HoLEP between 1998 and 2013 were identified.  
Patients with a known history of prostate cancer were excluded.  Multivariable logistic 
regression assessed variables associated with identification of prostate cancer on 
HoLEP specimens and Gleason 7 or higher prostate cancer among the malignant cases.  
Gleason grade was used as a proxy for disease severity.  Each of the models was 
adjusted for age, preoperative PSA, and HoLEP specimen weight. 
Results:  The cohort was comprised of 1272 patients of whom 103 (8.1%) had prostate 
cancer identified.  Prostate cancer cases had higher pre-HoLEP PSA (p=0.06) but lower 
HoLEP specimen weight (p=0.01).  On multivariate logistic regression, age and 
preoperative PSA were associated with increased odds of prostate cancer being present 
(p<0.01 each) while increasing HoLEP specimen weight was associated with decreased 
odds of prostate cancer (p<0.001).  Men older than 80 had 20% predicted probability of 
being diagnosed with prostate cancer.  Seventy-eight percent of prostate cancer cases 
were Gleason 6 or less.  Pre-HoLEP PSA was associated with increased adjusted odds 
of intermediate or high grade prostate cancer. 
Conclusion:  Prostate cancer identified by HoLEP is not uncommon but is generally low 
risk disease.  Older patients with smaller prostate glands have the highest odds of 
prostate cancer identification.  





















































































































































































































Benign prostatic hyperplasia (BPH) affects a significant proportion of men in the 
United States with 70% of men in their seventh decade demonstrating histologic 
evidence and 40% displaying moderate to severe urinary symptoms1.  Many will undergo 
active intervention with 912 per 100,000 men in the US undergoing a BPH procedure in 
20082.  While TURP remains the most common active intervention for BPH2,3, a well-
established alternative is holmium laser enucleation of the prostate (HoLEP).  HoLEP, 
initially described in 1996, reliably provides a more complete resection when compared 
with TURP, especially for large glands, with a superior safety profile4,5.  As with TURP, 
HoLEP is a procedure that provides tissue for pathologic analysis. 
Before the adoption of prostate specific antigen (PSA) screening, almost 20% of 
prostate cancer was diagnosed from TURP6-8.  However, since the introduction of PSA 
screening, this rate has declined significantly to 6-8%8.  Previous studies have 
demonstrated that up to 12% of men undergoing HoLEP will be found to have prostate 
cancer in their analyzed tissue9,10.  Most studies have suggested that prostate cancer 
identified on HoLEP is generally indolent but some men may ultimately require 
subsequent treatment of their prostate cancer. In our experience, post-HoLEP robot-
assisted radical prostatectomy, although feasible with encouraging oncologic outcomes, 
is a more challenging operation associated with longer functional recovery times 
compared to historical controls11.  Thus, identifying men at increased risk for clinically 
significant prostate cancer is an important consideration in managing patients with BPH 
disease who are considering enucleation surgery. 
Our primary objective was to identify the incidence of prostate cancer identified 
by HoLEP in men with no history of prostate cancer.  Additionally, we sought to 
determine preoperative variables that can be used to predict the presence of prostate 




















































































































































































































cancer in men undergoing HoLEP and to examine the burden of prostate cancer disease 
in this at risk patient population.  
 
Methods 
A retrospective analysis of patients who underwent HoLEP at IU Health 
Methodist Hospital between 1998 and 2013 was performed.  Patients with a prior history 
of prostate cancer diagnosis were eliminated from the analysis (n=34).  Pre-operative 
data including age, PSA, transrectal ultrasonography (TRUS) of prostatic volume, and 
PSA density were collected.  Additionally, post-operative data including final specimen 
weight and pathological tissue findings were recorded.  Patients without pre-operative 
PSA were eliminated (n=221). Patients with elevated PSAs (at the referring urologist’s 
discretion) had negative pre-operative prostate biopsies.  Prostate volume as assessed 
by TRUS was identified for 76% of patients.  PSA density was calculated from 
preoperative PSA and TRUS prostate volume and was available for 75% of patients.  
We acknowledge that the likelihood of identifying prostate cancer may vary between 
patients with a history of TRUS biopsy and those without; however, to the extent of our 
documentation, the detection of cancer at the time of HoLEP did not vary between 
patient populations (p=0.314).  
HoLEP was performed in similar fashion to our previously described technique12.  
Briefly, using a 550 micron end firing laser fiber through a 28 Fr continuous flow 
resectoscope, the transition zone of the prostate was completely enucleated.  Next, 
using a Lumenis morcellator (Yokneam, Israel), morcellation was completed removing 
the excised tissue from the bladder and prostatic fossa.  The entire HoLEP specimen 
was submitted for pathologic analysis by dedicated genitourinary pathologists. 
The relationship between pre- and post-operative variables and identification of 
the presence of prostate cancer was assessed using univariate and multivariate logistic 




















































































































































































































regression models.  A separate multivariate logistic regression model was performed on 
patients with prostate cancer to evaluate the relationship between preoperative variables 
and Gleason 7 or higher disease.  The variables chosen for univariate analyses were 
age, pre-operative PSA, pre-operative TRUS volume, final weight of prostate specimen 
from HoLEP, and percent of prostate resected.  For multivariate analyses, only age, pre-
operative PSA, and the HoLEP specimen weight were included.  As TRUS volume was 
not available for 24% of patients, we chose to use HoLEP specimen weight in the 
analysis as it was available for 97% of patients.  Patients with missing data were 
excluded from the regression analyses.  All statistical analyses were performed using 
Stata version 12.1 (Stata Corp. LP, College Station, TX).  In all tests, a two-tailed 
significance level of p<0.05 was used. Institutional Review Board approval was granted 
for the conduct of this study. 
 
Results 
 Patient pre-operative and post-operative characteristics are demonstrated in 
Table 1.  A total of 1272 patients undergoing HoLEP between 1998 and 2013 were 
analyzed.  One hundred and three (8.1%) patients had prostate cancer identified on final 
pathological prostatic tissue analysis.  Average pre-HoLEP PSA was 7.2ng/mL (range: 
0.04-121).  Of note, two patients had pre-HoLEP PSA values higher than 65ng/mL in the 
benign group (120, 121 ng/mL).  Both patients presented with retention and prostatitis 
prior to HoLEP.  Average volume resected during HoLEP was 78.9 grams (SD: 53).  The 
mean percent prostate tissue resected was 84%, which varied between 77% for the 
patients with prostate cancer and 85% among the non-malignant cases.  Patients with 
prostate cancer identified on final pathological analysis were older, had higher pre-
operative PSA, smaller pre-operative TRUS prostatic volume, and smaller HoLEP 
specimen weight (Table 1).  Length of stay was similar between the two groups.   




















































































































































































































Prediction of prostate cancer 
 On univariate logistic regression analysis, age and pre-operative PSA were 
significantly associated with increased odds of identifying prostate cancer on final 
pathological analysis after HoLEP (Table 2).  The weight of the HoLEP specimen was 
associated with decreased odds of prostate cancer identification in the HoLEP specimen 
(Table 2).  On multivariate logistic regression, age, pre-operative PSA and decreasing 
specimen weight remained significantly associated with the presence of prostate cancer 
(Table 2).  Figure 1 depicts the relationship between age and identification of prostate 
cancer when adjusting for pre-operative PSA and HoLEP specimen weight. Patients who 
were 80 years of age were at 20% predicted probability of having prostate cancer 
identified on HoLEP (<0.001). 
 
Prediction of Gleason 7 or higher prostate cancer 
 Of the 103 patients with prostate cancer, 80 were Gleason 6 or less (78%), 14 
were Gleason 7 (12 Gleason 3+4; 2 Gleason 4+3), and 9 were Gleason 8 or higher.  
Univariate regression results are shown in Table 3.  On multivariate logistic regression, 
increasing pre-operative PSA was associated with increased odds of Gleason 7 or 
greater prostate cancer (p=0.002) (Table 3).  
 Amongst the 103 patients identified with prostate cancer on HoLEP, follow-up 
information was available for 48.  Thirty-five of 48 patients (73%) were followed with 
active surveillance and had received no treatment for their diagnosed prostate cancer at 
last follow-up.  Twelve of the 48 patients (25%) underwent some form of primary 
therapy: 7 received external beam radiation, 3 underwent radical prostatectomy, and 2 
received hormonal therapy.  One patient with advanced disease underwent bilateral 
orchiectomy.  A total of three patients from this cohort had developed metastatic prostate 
cancer.  At last follow-up, three patients from the surveillance cohort had died of non-




















































































































































































































prostate cancer related causes while two men with metastatic disease in the intervention 
cohort had died. 
 
Discussion 
 Prior reports have identified the majority of prostate cancer in analyzed HoLEP 
tissue to be primarily low grade, indolent disease that has not required subsequent 
intervention.  A recent study by Rivera et al suggested that more than 90% of patients 
found to have prostate cancer at the time of HoLEP were managed successfully with 
active surveillance13.  Previous authors have reported a strong correlation between 
preoperative PSA and TRUS volume9,14.  Similar to simple prostatectomy for BPH, PSA 
values drop dramatically following HoLEP14,15 and subsequent increases in PSA-velocity 
are associated with increased risk of prostate malignancy9.  The PSA kinetics of patients 
discovered to have prostate cancer after HoLEP have not been well studied, although it 
would be reasonable to hypothesize that increases in PSA in this patient population may 
represent disease progression as the primary PSA-producing transition zone has been 
completely eliminated.  In our study, pre-operative PSA was the only variable associated 
with intermediate and high grade prostate cancer and it was significantly higher in the 
prostate cancer than benign cohorts.  As demonstrated in Figure 1, men older than 70 
years with smaller prostates were at the greatest risk of harboring prostate cancer and 
may warrant further workup prior to HoLEP.   
 A recent study by Zlotta et al found that 40% of men over 60 and nearly 60% of 
men over 80 had prostate cancer on autopsy specimen16.  Over 40% of the prostate 
cancer identified in this older group was found in the transition zone which is the primary 
prostatic tissue removed during HoLEP16.  These results contrast with our   finding of 
only 8% incidental prostate cancer in our HoLEP patients.  Despite this discordance, low 
rates of prostate cancer in HoLEP specimens was recently reported by Rivera et al who 




















































































































































































































cited a 13% cancer rate amongst their HoLEP patients13.  Differences in comparison with 
historical autopsy series may be at least partially attributable to the vast majority of 
HoLEP patients having regular PSA checks or, in some cases, pre-operative prostate 
biopsies.  Prior publications have suggested an association between BPH and prostate 
cancer that may be inflammatory mediated, even suggesting that the presence of BPH 
may increase the risk of malignancy17.  In contrast, our results suggest a potentially 
protective effect of BPH and obstructive symptoms on the presence of prostate cancer.  
Whether this represents a true cause and effect phenomenon or merely isolating a pre-
screened patient population remains unknown.  In any event, future research exploring 
the relationship between BPH and prostate cancer should be considered.  
 It is well established that the risk of prostate cancer increases with age.  Because 
BPH is the primary contributor to PSA rise and, as previously discussed, BPH may 
impact the incidence of prostate cancer, the relationship of prostate cancer in aging men 
with BPH is less understood.  Despite the fact that we report a significant increase in the 
adjusted odds of prostate cancer detection for each decade of life over 60 (Figure 1), we 
did not find that there was an association between age and Gleason score.  Although the 
relationship between age and prostate cancer was anticipated based on prior research, 
it does provide valuable support that the relationship between prostate cancer and age 
remains present even in men with co-existing BPH and obstructive symptoms, although 
it does not appear to impact the clinical significance of malignancy.  
Unlike the positive association between age and the presence of prostate cancer, 
the relationship between prostate size and prostate cancer has previously been shown 
to be inverse18.  Similar to prior findings, our cohort again demonstrated a decrease in 
the odds of prostate cancer identification as prostate gland size increased beyond 30g.  
Prior studies have hypothesized that the seemingly protective effect of larger glands 
harboring prostate cancer may be hormone mediated or related to a longer time before a 




















































































































































































































nodule penetrates the prostate capsule19.  Additionally, pre-operative PSA, TRUS 
volume, and PSA density were all significant on univariate analysis.  These findings 
suggest that prostate volume and PSA density may be important predictors of the 
presence of prostate cancer in men with BPH undergoing HoLEP and that these tests 
should be considered prior to surgery, particularly in men with higher risk of prostate 
cancer detection.  
 Although the limitations of PSA are well documented, PSA continues to be widely 
used as both a screening tool and a method of detecting prostate cancer recurrence20,21.  
Our results suggest that there is value in obtaining a PSA pre-operatively for men with 
BPH who are scheduled to undergo HoLEP.  All patients with an elevated PSA should 
be considered for prostate biopsy or repeat prostate biopsy before surgery.  If localized 
prostate cancer is identified prior to HoLEP, some of these men may elect to pursue 
alternative procedures to address both BPH and prostate cancer concomitantly. 
 Predicting the biologic behavior of prostate cancer found at HoLEP remains 
challenging.  As documented in the past on autopsy and whole mount tissue studies, 
typically only 20-40% of prostate cancer originates in the prostate transition zone16,22.  
Therefore, our data may be under-representing the true incidence and volume of 
disease present and is in no way a perfect surrogate for predicting prostate cancer-
related risk.  Despite this, interpretation of our results does allow us to make relevant 
observations regarding prostate malignancy in patients with BPH undergoing complete 
transition zone enucleation:  1) HoLEP candidates who are older men with small glands 
are more likely to harbor cancer in their enucleated tissue.  More specifically, 
independent of PSA and specimen weight, an estimated 20% of men who are at least 80 
years old will have prostate cancer identified on HoLEP specimen;  2) the number of 
patients with prostate cancer in this cohort is low (less than 10%) with predominantly low 
grade disease; and 3) pre-operative PSA may be predictive of both presence and 




















































































































































































































aggressiveness of disease.  Significantly, we have limited follow-up for our patients who 
were identified with prostate cancer on HoLEP as only 48 of the 103 continued to 
receive care at our institution. As we are a tertiary referral center, this is not unexpected; 
however, it does limit conclusions that can be drawn regarding the prognosis of patients 
diagnosed with prostate cancer from HoLEP specimen. 
 The majority of patients were outside referrals and cancer management was 
often directed by the referring provider and not captured in our database. For our internal 
HoLEP patient population diagnosed with prostate cancer, a general discussion of 
options was standard. Patients with low risk disease were recommended surveillance 
with a baseline PSA at six weeks followed by serial PSA checks and digital rectum 
exams every six months. Patients with a rising PSA or an abnormal exam were offered 
restaging TRUS biopsy and then treatment if indicated. Patients with intermediate and/or 
high risk disease post-HoLEP were staged appropriately and then offered definitive 
management, surgery vs radiation (external beam or IMRT) vs radiation and androgen 
deprivation typically without restaging biopsy.  
 Ultimately, the creation of a treatment and surveillance algorithm for managing 
this patient population based on numerous pre-operative variables is warranted.  Similar 
treatment flowcharts for prostate cancer and non-HoLEP related BPH procedures are 
well documented23.  Future studies that evaluate PSA kinetics in patients with prostate 
cancer identified by HoLEP will aid in determining appropriate follow-up 
recommendations for this unique population.  In our population of post-HoLEP patients 
with negative final prostate pathology, we anticipate PSA levels to fall below 1.  If levels 
do not nadir below 1 or rise quickly in follow-up, we recommend repeat TRUS prostate 
biopsy as suspicion for prostate cancer is high.  In the present study, our data offers 
potentially useful counseling data for patients prior to HoLEP regarding the risk of 




















































































































































































































prostate cancer being identified, as well as predicting higher risk disease in this patient 
population.  
 Our study has inherent limitations.  It is retrospective and the number of prostate 
cancer patients is relatively low.  Additionally, because a high percentage of our patients 
are referred from outside facilities, pre-operative TRUS techniques likely demonstrated 
inter-operator variability and TRUS volume was missing for a significant proportion of 
patients.  Because 24% of TRUS volumes were missing, we used HoLEP specimen 
weight in all of our analyses.  Additionally, TRUS biopsy was not standardized amongst 
referring physicians and this variable was not completely captured in our database. As a 
tertiary referral center, some post-HoLEP patients are lost to follow-up and therefore 
information on prostate cancer treatment initiation was not available for the entire cohort.  
It is possible that a disproportionate number of patients who required subsequent 
therapy received follow-up at our institution, thus creating a selection bias in the 
descriptive findings that we present.  Despite the stated limitations, our study represents 
one of the largest analyzed cohorts of prostate cancer in HoLEP patients. 
 
Conclusion 
 The existence of incidentally detected prostate cancer at the time of HoLEP in 
men with BPH and obstruction is low and the majority of patients will have low grade 
disease.  Men over 70 with smaller glands are at the highest risk of harboring prostate 
cancer in their analyzed tissue.  Optimal treatment and surveillance strategies for 
management of men with prostate cancer after HoLEP need to be established.  
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Table 1:  Holmium laser enucleation of the prostate:  patient characteristics 
 Benign Malignant p-value 
N 1169 103  
Age (years), mean (SD) 70.0 (8) 74.5 (9) <0.001 
Pre-operative PSA (ng/ml), mean (range) 7.0 (0.04-121a) 9.8 (0.13-61) 0.057 
Pre-operative TRUS volumeb (g), mean 
(range) 
101.4 (9-391) 85.2 (23-231) 0.012 
PSA densityb, mean (range) 0.08 (0.0-1.3) 0.19 (0.0-6.6) <0.001 
Final specimen weight, n (%)    
    <30g 191 (17) 29 (28) 
0.005 
    30-100g 602 (53) 57 (55) 
    100-150g 233 (21) 12 (12) 
    >150g 105 (9) 5 (5) 
Percent prostate resected, mean (SD) 84.9 (41) 77.0 (29) 0.115 
Length of stay (hours), mean (range) 29.3 (1-600) 33.8 (1-264) 0.233 
6 month post-HoLEP PSA (ng/mL), mean 
(range) 
1.2 (0.04-66) 4.5 (0.1-64) <0.001 
Abbreviations: SD, standard deviation; TRUS, transrectal ultrasound 
p-value represents Pearson’s chi-squared test or the Mann-Whitney test  
a Two patients in the benign group had pre-HoLEP PSAs higher than 65ng/mL. Both of 
these patients were admitted with retention and prostatitis. 

























































































































































































































Table 2:  Logistic regression analyses of variables associated with prostate 
cancer 
Univariate Odds Ratio 95% CI p-value 
Age 1.07 1.04-1.10 <0.001 
Pre-operative PSA 1.03 1.01-1.04 0.003 
Pre-operative TRUS volume 0.99 0.99-1.00 0.012 
Final weight of specimen    
    <30g REFERENCE   
    30-100g 0.62 0.39-1.00 0.052 
    100-150g 0.34 0.17-0.68 0.002 
    >150g 0.31 0.12-0.83 0.020 
Percent prostate resected 0.99 0.98-1.00 0.087 
PSA density 4.40 0.67-28.81 0.122 
Multivariate    
Age 1.07 1.04-1.10 <0.001 
Pre-operative PSA 1.03 1.01-1.05 0.003 
Final weight of specimen    
    <30g REFERENCE   
    30-100g 0.53 0.33-0.87 0.015 
    100-150g 0.25 0.12-0.51 <0.001 
    >150g 0.17 0.06-0.48 0.001 
 
  




















































































































































































































Table 3:  Variables associated with Gleason Score of 7 or higher in patients with 
prostate cancer  
Univariate Odds Ratio 95% CI p-value 
Age 1.03 0.97-1.09 0.318 
Pre-operative PSA 1.08 1.03-1.14 0.001 
Preoperative TRUS volume 1.00 0.98-1.01 0.810 
Final weight of specimen    
    <30g REFERENCE   
    30-100g 1.25 0.42-3.67 0.688 
    100-150g 0.77 0.13-4.47 0.768 
    >150g 0.96 0.09-10.23 0.972 
Multivariate    
Age 1.01 0.95-1.08 0.661 
Pre-operative PSA 1.08 1.03-1.14 0.002 
Final weight of specimen    
    <30g REFERENCE   
    30-100g 1.24 0.33-4.68 0.750 
    100-150g 0.78 0.11-5.51 0.805 
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